As expected, immunohistochemical analysis results revealed that CD8+ T cells, CD11b+Ly-6G+Ly-6Clow neutrophils, and NK cells were present at high density throughout the ZD55-IL-24-treated tumors, with less effective PBS treatment eliciting fewer CD8+ T cells, CD11b+Ly-6G+Ly-6Clow neutrophils, and NK cells in the bulk tumor mass (Fig. 3C–F), demonstrating that ZD55-IL-24 inhibited melanoma growth in B16-bearing immunocompetent mouse model through the indirect pathway of inducing antitumor immunity. The gene discussed is CD8A; the disease is melanoma.